These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Holst JJ Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141 [TBL] [Abstract][Full Text] [Related]
24. Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes. Edwards CM Br J Hosp Med (Lond); 2013 Apr; 74(4):198-201. PubMed ID: 23571389 [No Abstract] [Full Text] [Related]
26. [Modulation of the incretin effect in the treatment of diabetes]. Vidal J Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837 [TBL] [Abstract][Full Text] [Related]
27. [Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2]. Spasov AA; Chepljaeva NI Biomed Khim; 2015; 61(4):488-96. PubMed ID: 26350740 [TBL] [Abstract][Full Text] [Related]
29. Are we waiting too long for the cardiovascular outcome trials with the glucagon-like peptide-1 receptor agonists? Doggrell SA Expert Opin Drug Saf; 2015 Jun; 14(6):801-5. PubMed ID: 25891299 [TBL] [Abstract][Full Text] [Related]
30. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent. Lam NT; Kieffer TJ Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501 [TBL] [Abstract][Full Text] [Related]
31. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. Li L; Li S; Liu J; Deng K; Busse JW; Vandvik PO; Wong E; Sohani ZN; Bala MM; Rios LP; Malaga G; Ebrahim S; Shen J; Zhang L; Zhao P; Chen Q; Wang Y; Guyatt GH; Sun X BMC Cardiovasc Disord; 2016 May; 16():91. PubMed ID: 27169565 [TBL] [Abstract][Full Text] [Related]
32. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. Russell-Jones D Int J Clin Pract; 2010 Sep; 64(10):1402-14. PubMed ID: 20716148 [TBL] [Abstract][Full Text] [Related]
33. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?]. García-Casares N; García-Arnés JA; Gómez-Huelgas R; Valdivielso-Felices P; García-Arias C; González-Santos P Rev Neurol; 2014 Dec; 59(11):517-24. PubMed ID: 25418147 [TBL] [Abstract][Full Text] [Related]
34. The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis. Potts JE; Gray LJ; Brady EM; Khunti K; Davies MJ; Bodicoat DH PLoS One; 2015; 10(6):e0126769. PubMed ID: 26121478 [TBL] [Abstract][Full Text] [Related]
35. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders. Wroge J; Williams NT Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946 [TBL] [Abstract][Full Text] [Related]